Hantz Financial Services Inc. Purchases 7,858 Shares of GSK plc (NYSE:GSK)

Hantz Financial Services Inc. increased its position in shares of GSK plc (NYSE:GSK - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 87,416 shares of the pharmaceutical company's stock after buying an additional 7,858 shares during the quarter. Hantz Financial Services Inc.'s holdings in GSK were worth $2,956,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in GSK in the second quarter worth $52,487,000. Fisher Asset Management LLC boosted its stake in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after buying an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its holdings in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock valued at $144,803,000 after buying an additional 833,080 shares during the period. Finally, Bridgewater Associates LP raised its stake in shares of GSK by 107.3% in the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company's stock valued at $39,483,000 after buying an additional 500,010 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Up 0.8 %

Shares of NYSE:GSK opened at $35.35 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market cap of $73.27 billion, a P/E ratio of 22.96, a P/E/G ratio of 1.37 and a beta of 0.63. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company's 50-day moving average price is $34.04 and its two-hundred day moving average price is $37.71.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GSK. Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and reduced their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com cut shares of GSK from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.